Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oculis Holding AG (OCS : NSDQ)

• Company Description    Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland. Number of Employees: 60

• Price / Volume Information    Yesterday's Closing Price: $29.49 Daily Weekly Monthly 20 Day Moving Average: 462,648 shares Shares Outstanding: 57.98 (millions) Market Capitalization: $1,709.95 (millions) Beta: 0.38 52 Week High: $34.48 52 Week Low: $16.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.16% 4.78% 12 Week -1.67% -9.10% Year To Date 47.67% 42.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAHNHOFSTRASSE 20 - ZUG,V8 6300 CHE ph: 41-41-711-3960 fax: - ir@oculis.com http://www.oculis.com

• General Corporate Information    Officers Riad Sherif - Chief Executive Officer Anthony Rosenberg - Chairman Sylvia Cheung - Chief Financial Officer Christina Ackermann - Director Lionel Carnot - Director Peer Information Oculis Holding AG (CORR.) Oculis Holding AG (RSPI) Oculis Holding AG (CGXP) Oculis Holding AG (BGEN) Oculis Holding AG (GTBP) Oculis Holding AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H5870P102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/20/26 Share - Related Items Shares Outstanding: 57.98 Most Recent Split Date: (:1) Beta: 0.38 Market Capitalization: $1,709.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.21 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/20/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.81 Price/Cash Flow: - Price / Sales: 1,236.41 EPS Growth vs. Year Ago Period: 18.18% vs. Previous Quarter: -23.53% Sales Growth vs. Year Ago Period: -15.77% vs. Previous Quarter: -46.17% ROE 03/31/26 - -56.78 12/31/25 - -62.12 09/30/25 - -80.82 ROA 03/31/26 - -45.62 12/31/25 - -49.74 09/30/25 - -61.18 Current Ratio 03/31/26 - 5.18 12/31/25 - 5.96 09/30/25 - 4.47 Quick Ratio 03/31/26 - 5.18 12/31/25 - 5.96 09/30/25 - 4.47 Operating Margin 03/31/26 - -8,460.67 12/31/25 - -8,173.41 09/30/25 - -12,915.42 Net Margin 03/31/26 - -8,460.67 12/31/25 - -8,173.41 09/30/25 - -12,915.42 Pre-Tax Margin 03/31/26 - -8,653.00 12/31/25 - -8,269.94 09/30/25 - -12,947.55 Book Value 03/31/26 - 4.33 12/31/25 - 4.08 09/30/25 - 3.12 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.01 12/31/25 - 0.01 09/30/25 - 0.02 Debt-to-Capital 03/31/26 - 0.92 12/31/25 - 0.92 09/30/25 - 1.54

Powered by Zacks Investment Research ©